<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006924</url>
  </required_header>
  <id_info>
    <org_study_id>255164</org_study_id>
    <nct_id>NCT05006924</nct_id>
  </id_info>
  <brief_title>Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1</brief_title>
  <acronym>SOUL-DM1</acronym>
  <official_title>Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myotonic Dystrophy type 1 (DM1) is a multisystem disease that causes muscle weakness and&#xD;
      myotonia. As a result upper limb function might become impaired. In this study we will&#xD;
      examine patients with DM1 and record their upper limb function. We will will use a battery of&#xD;
      patient reported outcomes (PROs) and Outcome measures (OMs) in order to evalute which ones&#xD;
      are suitable for use in clinical practise and research studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Function Measures (MFM)</measure>
    <time_frame>30-45 minutes</time_frame>
    <description>Functional test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nine Hole Peg Test</measure>
    <time_frame>1-3 minutes</time_frame>
    <description>Fine motor function test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myogrip/Dynamometer</measure>
    <time_frame>1-3 minutes</time_frame>
    <description>Measures hand strenght</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myopinch</measure>
    <time_frame>1-3 minutes</time_frame>
    <description>Measures finger strenght</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ABILHAND Questionnaire</measure>
    <time_frame>5 min</time_frame>
    <description>A measure of manual ability for adults with upper limb impairments. The scale measures a person's ability to manage daily activities that require the use of the upper limbs, whatever the strategies involved. Consists of 22 questions (18 to be answered by adults). The categories are easy, difficult or unable to perform. The querionnaire gives a sum score where higher score equals better function.Score from 0 to 36</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACTIVLIM Questionnaire</measure>
    <time_frame>5 min</time_frame>
    <description>A measure of activity limitations for patients with upper and/or lower limb impairments. The scale measures a patient's ability to perform daily activities requiring the use of the upper and/or the lower limbs, whatever the strategies involved. Consists of 22 questions (18 to be answered by adults). The categories are easy, difficult or unable to perform. The questionnaire gives a sum score where higher score equals better function. Score fror 0 to 36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trunk Impairment Scale - modified Norwegian version</measure>
    <time_frame>8-15 minutes</time_frame>
    <description>Motor impairment of trunk measured by functional testing. Six subdomains measuring stability and mobility of trunkal movement. Min score 0 - Max score 16. Higher score indicates better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Four Square Step Test</measure>
    <time_frame>1-3 minutes</time_frame>
    <description>Dynamic balance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS29</measure>
    <time_frame>5-10 minutes</time_frame>
    <description>Questionnaire. Patient reported outcome measure. Generic health related quality of life assesses each of the 7 PROMIS domains (depresseion, anxiety, physical function, pain, fatigue, sleep disturbance and ability to participate in social roles). The PROMIS 29 questionnaire contains 4 questions from each of seven PROMIS contents (physical function, depression, anxiety, fatigue, sleep disorder, participation in social activities and pain interaction) and 1 question from the intensity of pain. Each item has 5 answer options (from 1 to 5), only pain intensity has 11 answer options (from 0 to 10). From the sum of the answers to each question in the domain, the total raw score for each domain is calculated, resulting in seven domain scores, each between 4 and 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Starkstein Apathy Scale</measure>
    <time_frame>5 minutes</time_frame>
    <description>Questionnaire to be filled in under guidance of interviewer. Patient reported outcome measure of apathy. 14 questions, each of which is scored on a 4-point scale of 0-3, and apathy is rated as severer as the total score (0-42) increases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>10 minutes</time_frame>
    <description>Cognitive assessment screening questionnaire. To be filled out in an interview setting. Score from 0 to 30, where a higher score indicates a better cognitive function. A score of 26 or more is considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function test</measure>
    <time_frame>10 minutes</time_frame>
    <description>Spirometry with FVC (Forced Vital Capasity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function test</measure>
    <time_frame>10 minutes</time_frame>
    <description>PEF (Peak Expiratory Flow).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Myotonic Dystrophy type 1 in Norway&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Genetically confirmed Myotonic Dystrophy type 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to answer or understand questionnaires due to language barriers or cognitive&#xD;
             status&#xD;
&#xD;
          -  Unable to perform functional tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin L Ørstavik, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hilde S Robinson, PHD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanne L Fossmo, MSC</last_name>
    <phone>+47 93630606</phone>
    <email>halufo@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petter S Sanaker, PHD</last_name>
      <email>petter.schandl.sanaker@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hispital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne L Fossmo, MSC</last_name>
      <phone>+4793630606</phone>
      <email>halufo@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Ørstavik, PHD</last_name>
      <email>krorstav@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Frambu Centre for Rare Disorders</name>
      <address>
        <city>Siggerud</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mari Ellefsen-Martinsen, MSC</last_name>
      <email>mae@frambu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Kristin Ørstavik</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Outcome measure</keyword>
  <keyword>Patient reported outcome</keyword>
  <keyword>Upper limb function</keyword>
  <keyword>arm- and hand function</keyword>
  <keyword>Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

